Press Releases 2010
- December 28, 2010
Florida Hospital, Sanford-Burnham Medical Research Institute and Takeda Announce Partnership to Target Obesity - December 22, 2010
Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) - December 17, 2010
-Takeda Well-Being Program 2010 - "Giving Children in Long-term Treatment the Energy to Live" - December 8, 2010
WEEKLY VELCADE IN COMBINATION WITH RITUXIMAB IMPROVES PROGRESSION-FREE SURVIVAL AND RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
-- Addition of VELCADE increased progression-free survival by 22 percent -- - December 8, 2010
SUBCUTANEOUS ADMINISTRATION OF SINGLE-AGENT VELCADE DEMONSTRATES EFFICACY CONSISTENT WITH INTRAVENOUS ADMINISTRATION
--Overall Response Rate 42 Percent in Both Arms--
--Subcutaneous Administration Shows 63 Percent Reduction in Severe Peripheral Neuropathy-- - December 8, 2010
Orexigen® Therapeutics' Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity - December 8, 2010
Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual Meeting
-97 Percent of Patients Had Reductions in Tumor Volume-
-53 Percent of Patients Achieved Complete Remission-
-BLA Submission for Relapsed or Refractory Hodgkin Lymphoma and ALCL Planned in First Quarter of 2011; Planned Marketing Authorization Application (MAA) Submission in First Half of 2011 Under Discussion with European Regulators- - December 6, 2010
Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
-94 Percent of Patients Had Reductions in Tumor Volume-
-34 Percent of Patients Achieved Complete Remission-
-BLA Submission for Relapsed or Refractory Hodgkin Lymphoma and ALCL Planned in First Quarter of 2011; Planned MAA Submission in First Half of 2011 Under Discussion with European Regulators- - December 2, 2010
BAXTER AND TAKEDA COMPLETE AGREEMENT FOR VERO-CELL BASED INFLUENZA VACCINES IN JAPAN - November 29, 2010
AFFYMAX AND TAKEDA CONFIRM U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, FOLLOWING MEETING WITH FDA
- Companies Confirm Q2 2011 Timeline for NDA Submission - - November 29, 2010
Application for a Change to the Dosage and Administration of Central Precocious Puberty Medications: Leuplin® for Injection 1.88 and Leuplin® for Injection 3.75 - November 11, 2010
VELCADE® (BORTEZOMIB) INDUCTION AND MAINTENANCE DATA TO BE FEATURED IN ORAL PRESENTATIONS AT AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING - November 11, 2010
Takeda and Sage Bionetworks Form CNS disease Research Alliance - November 4, 2010
MILLENNIUM AND TAKEDA ANNOUNCE ADVANCEMENT OF PROSTATE CANCER PROGRAM - October 29, 2010
Takeda Expands the Scope of its Corporate Venture Activities with the Formation of Takeda Ventures, Inc. - October 26, 2010
Takeda Announces Top Line Results from Phase 2 Study of Investigational Compound, TAK-442 for the patients with ACS - October 22, 2010
The London Symphony Orchestra Tours Japan under the Takeda Global Concert Series Program - October 22, 2010
Receipt of the Health, Labour and Welfare Minister’s Award, the Awards for Achievement in Promoting “Reduce, Reuse, Recycle” Activities for fiscal 2010 - October 20, 2010
Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for the Treatment of Essential Hypertension - October 19, 2010
Takeda to Obtain Full Ownership of Tianjin Takeda Pharmaceuticals Co., Ltd. through Acquisition of Equity Held by Tianjin Lisheng Pharmaceutical - October 18, 2010
A New Phase for Takeda's Global Business Development Organization - October 13, 2010
Japan Health Sciences Foundation and Takeda Enter into License Agreement Concerning Exclusive Use of Patent Rights of Human Papillomavirus (HPV) Vaccine - October 8, 2010
Takeda and Envoy Form Schizophrenia Research Alliance - October 7, 2010
Renovation of the Takeda Garden for Medicinal Plant Conservation, Kyoto - October 1, 2010
Takeda Appoints Mr. Bruno Angelici as a New Member of “Takeda Global Advisory Board” - October 1, 2010
Takeda Announces Basic Strategies for Expansion into India - September 30, 2010
Takeda Announces Changes in Management of Pharmaceutical Research Division - September 28, 2010
Takeda Debuts on the Dow Jones Sustainability Asia Pacific Index - September 22, 2010
PATIENTS LIVING WITH GERD NOW HAVE A NEW TREATMENT OPTION FOR IMPROVED AND SUSTAINED SYMPTOM RELIEF
DEXILANT is the First Proton Pump Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology - September 17, 2010
Takeda to Construct New Manufacturing Facilities for Pharmaceutical Products within its Hikari Plant Premise in Japan - September 2, 2010
Orexigen® Therapeutics and Takeda Enter into Partnership to Commercialize Contrave® in North America - August 31, 2010
Takeda Announces New Initiative in Cell Culture-Based Influenza Vaccines - August 20, 2010
Approval of Additional Indication of NESINA®: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan - August 20, 2010
Approval of an Additional Indication of “Takepron® Capsules 15” and “Takepron® OD Tablets 15” for Prevention of Recurrence of NSAIDs-Associated Gastric Ulcer/Duodenal Ulcer in Japan - August 5, 2010
AFFYMAX AND TAKEDA ANNOUNCE PRELIMINARY U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE - July 30, 2010
Takeda Announces the Appointment of Executive Vice President, International Operations (Americas/Europe) and Senior Vice President, International Operations (Asia), the establishment of new organization - July 30, 2010
Takeda Expands International Operations Leadership - July 23, 2010
Approval of an Additional Indication of “Takepron® Capsules 15” and “Takepron® OD Tablets 15” in Japan for Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer during Low-dose Aspirin Administration - July 16, 2010
Approval of Lampion® Pack in Japan for Secondary Eradication of Helicobacter pylori - July 12, 2010
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - July 9, 2010
Takeda Included in the FTSE4Good Global Index for the Sixth Consecutive Year - July 6, 2010
Launches of “ROZEREM®” for treatment of insomnia, “METACT®” for treatment of type 2 diabetes and Actos® Orally Disintegrating Tablets for treatment of type 2 diabetes in Japan - June 29, 2010
AMAG Pharmaceuticals and Takeda Announce Acceptance of Submission of Feraheme® Marketing Authorization Application to the European Medicines Agency and Initiation of Global Registrational Program for Feraheme for the Treatment of Iron Deficiency Anemia - June 28, 2010
Takeda Appoints Two Executive-level Personnel from Outside the Company - June 28, 2010
Takeda Announces Appointment of New Executive and Corporate Officer - June 25, 2010
Takeda Announces Appointment of New Corporate Officers - June 25, 2010
Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - June 23, 2010
Takeda to Expand Presence in Asia with Operations in South Korea - June 22, 2010
ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
First and only fixed-dose combination oral antidiabetic medication with extended-release metformin available in once-daily dosing - June 21, 2010
AFFYMAX AND TAKEDA ANNOUNCE PHASE 3 TRIALS MEET PRIMARY ENDPOINTS FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE WITH SOME DIFFERENCES NOTED IN SECONDARY ANALYSES - June 18, 2010
Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors - June 17, 2010
CanBas and Takeda to Terminate Collaboration for CBP501 for the Treatment of Cancer - June 15, 2010
Launches of “NESINA®” for treatment of type 2 diabetes, “UNISIA®” for treatment of hypertension and “Vectibix®”, anti-cancer agent, in Japan - June 2, 2010
Takeda Achieves Zero Emissions at its Plants in Japan - May 21, 2010
Takeda Announces Change in Management with the Establishment of New Organization - May 12, 2010
2010-2012 Mid-Range Plan Transformation for a New Takeda - May 10, 2010
Takeda to Co-promote VELCADE® (bortezomib) for Injection in Japan
--Takeda continues to build global presence in oncology-- - May 7, 2010
Announcement regarding Establishment of Sponsored ADR Program - April 28, 2010
Takeda Provides Update on Patent Litigation for ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the U.S.
Takeda Announces Assumption for FY 2010 Financial Outlook and Mid-Range Plan - April 28, 2010
Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension - April 16, 2010
New Drug Applications Approval for Five New Products in Japan - April 13, 2010
Takeda’s Annual Report 2009 and CSR Data Book 2009 receive third prize in Sustainability Reporting Award - April 8, 2010
Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma
-AETHERA trial designed to support full approval in the United States and Europe-
-Data from ongoing pivotal trial to be reported in second half of 2010 and provide basis for NDA and MAA submissions in the first half of 2011 - - April 1, 2010
AMAG Pharmaceuticals and Takeda Pharmaceutical Company Announce Strategic Collaboration for Feraheme® in All Therapeutic Indications in Select Ex-US Territories, Including Europe - April 1, 2010
About Agreement Reached to Co-market R113675 (Galantamine Hydrobromide), a Treatment for Alzheimer’s Disease - March 25, 2010
Takeda Submits Application in Japan for Additional Indications of Alogliptin for Combination Therapy with Sulfonylurea and Combination Therapy with Biguanide - March 19, 2010
Takeda Announces Withdrawal of Marketing Authorization Application for a Prolonged-Release Formulation of Competact® and discontinuation of its development in the EU - March 18, 2010
Takeda Launches Initiative for Capacity Development of Health Care Workers in Africa through programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria - March 16, 2010
A Once-Monthly Formulation of Risedronate Sodium Hydrate for the Treatment of Osteoporosis Entered Into Phase 3 Clinical Programs in Japan - March 5, 2010
KAPIDEX™ (dexlansoprazole) Renamed DEXILANT™ in U.S. to Avoid Name Confusion - March 3, 2010
Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 - February 23, 2010
Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Phase 2 Extension Study Demonstrated Sustained Weight Loss - February 18, 2010
HEMATIDE™ ENTERED INTO THE PHASE 3 CLINICAL PROGRAM TO TREAT ANEMIA IN CHRONIC RENAL FAILURE PATIENTS IN JAPAN - February 1, 2010
FIRST TREATMENT TO IMPROVE SURVIVAL IN 20 YEARS NOW AVAILABLE FOR PATIENTS WITH OSTEOSARCOMA (BONE CANCER) - January 18, 2010
Approval of Actos® Orally Disintegrating Tablets in Japan